We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
-0.31%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+436.07%
AUM
$111B
AUM Growth
+$1.46B
Cap. Flow
+$2.6B
Cap. Flow %
2.33%
Top 10 Hldgs %
23.97%
Holding
4,345
New
253
Increased
2,150
Reduced
1,535
Closed
239

Sector Composition

Rank Sector Weight
1 Technology 14.74%
2 Financials 9%
3 Healthcare 8.22%
4 Consumer Discretionary 6.53%
5 Industrials 6.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
SYBX
3926
DELISTED
Synlogic
SYBX
$34K ﹤0.01%
+733
New +$34.2K
TTOO
3927
DELISTED
T2 Biosystems, Inc
TTOO
$34K ﹤0.01%
7
DISH
3928
CALL
DELISTED
DISH Network Corp.
DISH
$34K ﹤0.01%
19,000
-600
-3% -$25.5K
BIOR
3929
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
$33K ﹤0.01%
88
GLW icon
3930
CALL
Corning
GLW
$137B
$32K ﹤0.01%
53,300
MDT icon
3931
CALL
Medtronic
MDT
$116B
$32K ﹤0.01%
53,900
+11,100
+26% +$1.44M
IRCP
3932
DELISTED
IRSA Propiedades Comerciales S.A.
IRCP
$32K ﹤0.01%
+10,899
New +$28.2K
PRU icon
3933
CALL
Prudential Financial
PRU
$42.2B
$31K ﹤0.01%
+44,500
New +$4.59M
TLT icon
3934
PUT
iShares 20+ Year Treasury Bond ETF
TLT
$40.6B
$31K ﹤0.01%
12,800
TROX icon
3935
CALL
Tronox
TROX
$1.02B
$31K ﹤0.01%
+12,100
New +$248K
MLSS icon
3936
Milestone Scientific
MLSS
$43M
$30K ﹤0.01%
16,000
UPC icon
3937
Universe Pharmaceuticals Inc
UPC
$3.85M
$30K ﹤0.01%
+3
New +$27.6K
LOB icon
3938
CALL
Live Oak Bancshares
LOB
$1.98B
$29K ﹤0.01%
12,500
-23,400
-65% -$1.39M
RMTI icon
3939
Rockwell Medical
RMTI
$27.9M
$29K ﹤0.01%
440
-53
-11% -$4.02K
HEXO
3940
DELISTED
HEXO Corp. Common Shares
HEXO
$29K ﹤0.01%
1,121
+15
+1% +$696
BODY.WS
3941
DELISTED
The Beachbody Company, Inc. Redeemable Warrants, each whole warrant exercisable for one share of Class A Common Stock at an exercise price of $11.50
BODY.WS
$28K ﹤0.01%
23,699
-8,001
-25% -$16.3K
APD icon
3942
CALL
Air Products & Chemicals
APD
$68.9B
$27K ﹤0.01%
30,200
-900
-3% -$249K
CVX icon
3943
CALL
Chevron
CVX
$386B
$27K ﹤0.01%
20,800
-57,600
-73% -$5.75M
IFRX icon
3944
InflaRx
IFRX
$295M
$27K ﹤0.01%
10,419
-9,500
-48% -$25K
PII icon
3945
CALL
Polaris
PII
$3.99B
$27K ﹤0.01%
15,200
-100
-0.7% -$12.7K
PLUR icon
3946
Pluri
PLUR
$18.9M
$27K ﹤0.01%
1,282
SEAC
3947
DELISTED
Seachange International Inc
SEAC
$27K ﹤0.01%
1,250
CELP
3948
DELISTED
Cypress Environmental Partners, L.P.
CELP
$27K ﹤0.01%
15,000
-19,500
-57% -$35.1K
AXON
3949
CALL
Axon Enterprise
AXON
$51.7B
$26K ﹤0.01%
+10,100
New +$1.83M
INFY icon
3950
CALL
Infosys
INFY
$51B
$26K ﹤0.01%
+29,100
New +$658K

Similar funds

Raymond James & Associates's Q3 2021 Portfolio in Review

As of Q3 2021, Raymond James & Associates held 4,345 positions worth $111B, up 1.3% from $110B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Raymond James & Associates's Q3 2021 filing shows 253 new, 2,150 increased, 1,535 reduced and 239 closed positions. Its largest new stake was GXO Logistics: 224,392 shares worth $17.6M. The largest sale was iShares Core S&P Mid-Cap ETF, an estimated $358M.

By sector, the portfolio is most concentrated in Technology at 15% of assets, up from 14% a quarter earlier, followed by Financials and Healthcare.

  • Raymond James & Associates's largest Q3 2021 buy was GXO Logistics: 224,392 shares worth $17.6M.
  • Raymond James & Associates added most to Vanguard Morningstar Mid-Cap ETF in Q3 2021, an estimated $569M increase.
  • Raymond James & Associates's biggest Q3 2021 reduction was iShares Core S&P Mid-Cap ETF, cutting an estimated $358M.
  • Raymond James & Associates fully exited Invesco S&P 500 Equal Weight Energy ETF in Q3 2021, selling an estimated $9.16M.
  • Raymond James & Associates's ten largest holdings make up 24% of its $111B portfolio in Q3 2021.
  • Raymond James & Associates opened 253 new positions and closed 239 in Q3 2021.
  • Raymond James & Associates's portfolio value rose 1.3% quarter-over-quarter to $111B.

Based on Raymond James & Associates's 13F filing for Q3 2021, filed 2 Nov 2021.